Skip to content

Amgen

NASDAQ: AMGN · USD

Amgen financials

6 charts

Revenue

USD millions

$10,054M
Amgen Revenue. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodRevenue
FY 2009 Q2$3,713M; Change unavailable vs FY 2009 Q1
FY 2009 Q3$3,812M; +2.7% vs FY 2009 Q2
FY 2009 Q4$3,809M; −0.1% vs FY 2009 Q3
FY 2010 Q1$3,592M; −5.7% vs FY 2009 Q4
FY 2010 Q2$3,804M; +5.9% vs FY 2010 Q1
FY 2010 Q3$3,816M; +0.3% vs FY 2010 Q2
FY 2010 Q4$3,841M; +0.7% vs FY 2010 Q3
FY 2011 Q1$3,706M; −3.5% vs FY 2010 Q4
FY 2011 Q2$3,959M; +6.8% vs FY 2011 Q1
FY 2011 Q3$3,944M; −0.4% vs FY 2011 Q2
FY 2011 Q4$3,973M; +0.7% vs FY 2011 Q3
FY 2012 Q1$4,048M; +1.9% vs FY 2011 Q4
FY 2012 Q2$4,477M; +10.6% vs FY 2012 Q1
FY 2012 Q3$4,319M; −3.5% vs FY 2012 Q2
FY 2012 Q4$4,421M; +2.4% vs FY 2012 Q3
FY 2013 Q1$4,238M; −4.1% vs FY 2012 Q4
FY 2013 Q2$4,679M; +10.4% vs FY 2013 Q1
FY 2013 Q3$4,748M; +1.5% vs FY 2013 Q2
FY 2013 Q4$5,011M; +5.5% vs FY 2013 Q3
FY 2014 Q1$4,521M; −9.8% vs FY 2013 Q4
FY 2014 Q2$5,180M; +14.6% vs FY 2014 Q1
FY 2014 Q3$5,031M; −2.9% vs FY 2014 Q2
FY 2014 Q4$5,331M; +6.0% vs FY 2014 Q3
FY 2015 Q1$5,033M; −5.6% vs FY 2014 Q4
FY 2015 Q2$5,370M; +6.7% vs FY 2015 Q1
FY 2015 Q3$5,723M; +6.6% vs FY 2015 Q2
FY 2015 Q4$5,536M; −3.3% vs FY 2015 Q3
FY 2016 Q1$5,527M; −0.2% vs FY 2015 Q4
FY 2016 Q2$5,688M; +2.9% vs FY 2016 Q1
FY 2016 Q3$5,811M; +2.2% vs FY 2016 Q2
FY 2016 Q4$5,965M; +2.7% vs FY 2016 Q3
FY 2017 Q1$5,464M; −8.4% vs FY 2016 Q4
FY 2017 Q2$5,810M; +6.3% vs FY 2017 Q1
FY 2017 Q3$5,773M; −0.6% vs FY 2017 Q2
FY 2017 Q4$5,802M; +0.5% vs FY 2017 Q3
FY 2018 Q1$5,554M; −4.3% vs FY 2017 Q4
FY 2018 Q2$6,059M; +9.1% vs FY 2018 Q1
FY 2018 Q3$5,904M; −2.6% vs FY 2018 Q2
FY 2018 Q4$6,230M; +5.5% vs FY 2018 Q3
FY 2019 Q1$5,557M; −10.8% vs FY 2018 Q4
FY 2019 Q2$5,871M; +5.7% vs FY 2019 Q1
FY 2019 Q3$5,737M; −2.3% vs FY 2019 Q2
FY 2019 Q4$6,197M; +8.0% vs FY 2019 Q3
FY 2020 Q1$6,161M; −0.6% vs FY 2019 Q4
FY 2020 Q2$6,206M; +0.7% vs FY 2020 Q1
FY 2020 Q3$6,423M; +3.5% vs FY 2020 Q2
FY 2020 Q4$6,634M; +3.3% vs FY 2020 Q3
FY 2021 Q1$5,901M; −11.0% vs FY 2020 Q4
FY 2021 Q2$6,526M; +10.6% vs FY 2021 Q1
FY 2021 Q3$6,706M; +2.8% vs FY 2021 Q2
FY 2021 Q4$6,846M; +2.1% vs FY 2021 Q3
FY 2022 Q1$6,238M; −8.9% vs FY 2021 Q4
FY 2022 Q2$6,594M; +5.7% vs FY 2022 Q1
FY 2022 Q3$6,652M; +0.9% vs FY 2022 Q2
FY 2022 Q4$6,839M; +2.8% vs FY 2022 Q3
FY 2023 Q1$6,105M; −10.7% vs FY 2022 Q4
FY 2023 Q2$6,986M; +14.4% vs FY 2023 Q1
FY 2023 Q3$6,903M; −1.2% vs FY 2023 Q2
FY 2023 Q4$8,196M; +18.7% vs FY 2023 Q3
FY 2024 Q1$7,447M; −9.1% vs FY 2023 Q4
FY 2024 Q2$8,388M; +12.6% vs FY 2024 Q1
FY 2024 Q3$8,503M; +1.4% vs FY 2024 Q2
FY 2024 Q4$9,086M; +6.9% vs FY 2024 Q3
FY 2025 Q1$8,149M; −10.3% vs FY 2024 Q4
FY 2025 Q2$9,179M; +12.6% vs FY 2025 Q1
FY 2025 Q3$9,557M; +4.1% vs FY 2025 Q2
FY 2025 Q4$9,866M; +3.2% vs FY 2025 Q3
FY 2026 Q1$8,618M; −12.6% vs FY 2025 Q4
FY 2026 Q2$10,054M; +16.7% vs FY 2026 Q1
Jun 30, 2009 through Sep 25, 2026

Free cash flow

USD millions

$3,489M
Amgen Free cash flow. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodFree cash flow
FY 2009 Q2$1,540M; Change unavailable vs FY 2009 Q1
FY 2009 Q3$1,845M; +19.8% vs FY 2009 Q2
FY 2009 Q4$1,679M; −9.0% vs FY 2009 Q3
FY 2010 Q1$819M; −51.2% vs FY 2009 Q4
FY 2010 Q2$1,387M; +69.4% vs FY 2010 Q1
FY 2010 Q3$1,175M; −15.3% vs FY 2010 Q2
FY 2010 Q4$1,826M; +55.4% vs FY 2010 Q3
FY 2011 Q1$930M; −49.1% vs FY 2010 Q4
FY 2011 Q2$1,413M; +51.9% vs FY 2011 Q1
FY 2011 Q3$849M; −39.9% vs FY 2011 Q2
FY 2011 Q4$1,360M; +60.2% vs FY 2011 Q3
FY 2012 Q1$828M; −39.1% vs FY 2011 Q4
FY 2012 Q2$2,203M; +166.1% vs FY 2012 Q1
FY 2012 Q3$1,550M; −29.6% vs FY 2012 Q2
FY 2012 Q4$612M; −60.5% vs FY 2012 Q3
FY 2013 Q1$891M; +45.6% vs FY 2012 Q4
FY 2013 Q2$1,441M; +61.7% vs FY 2013 Q1
FY 2013 Q3$1,632M; +13.3% vs FY 2013 Q2
FY 2013 Q4$1,634M; +0.1% vs FY 2013 Q3
FY 2014 Q1$970M; −40.6% vs FY 2013 Q4
FY 2014 Q2$2,054M; +111.8% vs FY 2014 Q1
FY 2014 Q3$2,571M; +25.2% vs FY 2014 Q2
FY 2014 Q4$2,242M; −12.8% vs FY 2014 Q3
FY 2015 Q1$1,211M; −46.0% vs FY 2014 Q4
FY 2015 Q2$2,681M; +121.4% vs FY 2015 Q1
FY 2015 Q3$2,736M; +2.1% vs FY 2015 Q2
FY 2015 Q4$1,855M; −32.2% vs FY 2015 Q3
FY 2016 Q1$1,759M; −5.2% vs FY 2015 Q4
FY 2016 Q2$2,489M; +41.5% vs FY 2016 Q1
FY 2016 Q3$2,495M; +0.2% vs FY 2016 Q2
FY 2016 Q4$2,873M; +15.2% vs FY 2016 Q3
FY 2017 Q1$2,217M; −22.8% vs FY 2016 Q4
FY 2017 Q2$2,141M; −3.4% vs FY 2017 Q1
FY 2017 Q3$3,296M; +53.9% vs FY 2017 Q2
FY 2017 Q4$2,859M; −13.3% vs FY 2017 Q3
FY 2018 Q1$2,572M; −10.0% vs FY 2017 Q4
FY 2018 Q2$1,915M; −25.5% vs FY 2018 Q1
FY 2018 Q3$3,102M; +62.0% vs FY 2018 Q2
FY 2018 Q4$2,969M; −4.3% vs FY 2018 Q3
FY 2019 Q1$1,729M; −41.8% vs FY 2018 Q4
FY 2019 Q2$1,270M; −26.5% vs FY 2019 Q1
FY 2019 Q3$3,207M; +152.5% vs FY 2019 Q2
FY 2019 Q4$2,326M; −27.5% vs FY 2019 Q3
FY 2020 Q1$1,992M; −14.4% vs FY 2019 Q4
FY 2020 Q2$2,684M; +34.7% vs FY 2020 Q1
FY 2020 Q3$3,233M; +20.5% vs FY 2020 Q2
FY 2020 Q4$1,980M; −38.8% vs FY 2020 Q3
FY 2021 Q1$1,938M; −2.1% vs FY 2020 Q4
FY 2021 Q2$1,746M; −9.9% vs FY 2021 Q1
FY 2021 Q3$2,176M; +24.6% vs FY 2021 Q2
FY 2021 Q4$2,521M; +15.9% vs FY 2021 Q3
FY 2022 Q1$1,974M; −21.7% vs FY 2021 Q4
FY 2022 Q2$1,684M; −14.7% vs FY 2022 Q1
FY 2022 Q3$2,818M; +67.3% vs FY 2022 Q2
FY 2022 Q4$2,309M; −18.1% vs FY 2022 Q3
FY 2023 Q1$720M; −68.8% vs FY 2022 Q4
FY 2023 Q2$3,838M; +433.1% vs FY 2023 Q1
FY 2023 Q3$2,512M; −34.5% vs FY 2023 Q2
FY 2023 Q4$289M; −88.5% vs FY 2023 Q3
FY 2024 Q1$459M; +58.8% vs FY 2023 Q4
FY 2024 Q2$2,221M; +383.9% vs FY 2024 Q1
FY 2024 Q3$3,314M; +49.2% vs FY 2024 Q2
FY 2024 Q4$4,400M; +32.8% vs FY 2024 Q3
FY 2025 Q1$980M; −77.7% vs FY 2024 Q4
FY 2025 Q2$1,911M; +95.0% vs FY 2025 Q1
FY 2025 Q3$4,248M; +122.3% vs FY 2025 Q2
FY 2025 Q4$961M; −77.4% vs FY 2025 Q3
FY 2026 Q1$1,477M; +53.7% vs FY 2025 Q4
FY 2026 Q2$3,489M; +136.2% vs FY 2026 Q1

Net margin

%

23.62%
Amgen Net margin. Reported fiscal history.
Fiscal period%
FY 2009 Q234.18%
FY 2009 Q336.36%
FY 2009 Q424.44%
FY 2010 Q132.49%
FY 2010 Q231.6%
FY 2010 Q332.39%
FY 2010 Q426.61%
FY 2011 Q130.36%
FY 2011 Q229.55%
FY 2011 Q311.51%
FY 2011 Q423.51%
FY 2012 Q129.25%
FY 2012 Q228.28%
FY 2012 Q325.63%
FY 2012 Q417.82%
FY 2013 Q133.84%
FY 2013 Q226.89%
FY 2013 Q328.81%
FY 2013 Q420.38%
FY 2014 Q123.73%
FY 2014 Q229.86%
FY 2014 Q324.73%
FY 2014 Q424.27%
FY 2015 Q132.25%
FY 2015 Q230.78%
FY 2015 Q332.55%
FY 2015 Q432.51%
FY 2016 Q134.38%
FY 2016 Q232.88%
FY 2016 Q334.71%
FY 2016 Q432.44%
FY 2017 Q137.9%
FY 2017 Q237.02%
FY 2017 Q335.01%
FY 2017 Q4-73.49%
FY 2018 Q141.61%
FY 2018 Q237.89%
FY 2018 Q331.49%
FY 2018 Q430.95%
FY 2019 Q135.85%
FY 2019 Q237.11%
FY 2019 Q334.3%
FY 2019 Q427.48%
FY 2020 Q129.62%
FY 2020 Q229.05%
FY 2020 Q331.47%
FY 2020 Q424.34%
FY 2021 Q127.89%
FY 2021 Q27.11%
FY 2021 Q328.09%
FY 2021 Q427.74%
FY 2022 Q123.66%
FY 2022 Q219.97%
FY 2022 Q332.22%
FY 2022 Q423.63%
FY 2023 Q146.54%
FY 2023 Q219.74%
FY 2023 Q325.06%
FY 2023 Q49.36%
FY 2024 Q1-1.52%
FY 2024 Q28.89%
FY 2024 Q333.28%
FY 2024 Q46.9%
FY 2025 Q121.23%
FY 2025 Q215.6%
FY 2025 Q333.65%
FY 2025 Q413.51%
FY 2026 Q121.11%
FY 2026 Q223.62%

P/E

× · TTM · Daily

25.8×
Amgen P/E. Monthly closing observations; inspect daily values with the chart arrow keys.
Close date× · TTM · DailyFinancials through
2012-03-3014.42×2010-09-30
2012-04-3015.08×2010-09-30
2012-05-3114.74×2010-09-30
2012-06-2915.46×2010-09-30
2012-07-3117.52×2010-09-30
2012-08-3117.8×2010-09-30
2012-09-2817.88×2010-09-30
2012-10-3118.34×2010-09-30
2012-11-3018.83×2010-09-30
2012-12-3118.28×2010-09-30
2013-01-3118.12×2010-09-30
2013-02-2816.46×2012-12-31
2013-03-2818.43×2012-12-31
2013-04-3018.73×2012-12-31
2013-05-3118.07×2012-12-31
2013-06-2817.73×2012-12-31
2013-07-3119.47×2012-12-31
2013-08-3019.58×2012-12-31
2013-09-3020.12×2012-12-31
2013-10-3120.88×2012-12-31
2013-11-2920.51×2012-12-31
2013-12-3120.51×2012-12-31
2014-01-3121.38×2012-12-31
2014-02-2822.29×2012-12-31
2014-03-3122.17×2012-12-31
2014-04-3020.09×2012-12-31
2014-05-3019.29×2013-03-31
2014-06-3019.68×2013-03-31
2014-07-3121.18×2013-03-31
2014-08-2923.21×2013-06-30
2014-09-3023.39×2013-06-30
2014-10-3125.6×2014-09-30
2014-11-2826.09×2014-09-30
2014-12-3125.14×2014-09-30
2015-01-3024.03×2014-09-30
2015-02-2723.64×2014-12-31
2015-03-3123.95×2014-12-31
2015-04-3021.3×2015-03-31
2015-05-2921.08×2015-03-31
2015-06-3020.71×2015-03-31
2015-07-3123.82×2015-03-31
2015-08-3120.05×2015-06-30
2015-09-3018.27×2015-06-30
2015-10-3020.89×2015-06-30
2015-11-3019.13×2015-09-30
2015-12-3119.28×2015-09-30
2016-01-2918.14×2015-09-30
2016-02-2915.65×2015-12-31
2016-03-3116.49×2015-12-31
2016-04-2917.41×2015-12-31
2016-05-3116.64×2016-03-31
2016-06-3016.02×2016-03-31
2016-07-2918.12×2016-03-31
2016-08-3117.3×2016-06-30
2016-09-3016.97×2016-06-30
2016-10-3114.01×2016-09-30
2016-11-3014.3×2016-09-30
2016-12-3014.51×2016-09-30
2017-01-3115.55×2016-09-30
2017-02-2817.52×2016-09-30
2017-03-3116.28×2016-09-30
2017-04-2815.33×2017-03-31
2017-05-3114.57×2017-03-31
2017-06-3016.17×2017-03-31
2017-07-3115.76×2017-06-30
2017-08-3116.05×2017-06-30
2017-09-2916.83×2017-06-30
2017-10-3115.71×2017-09-30
2017-11-3015.74×2017-09-30
2017-12-2915.59×2017-09-30
2018-01-3116.68×2017-09-30
2018-02-2867.43×2017-12-31
2018-03-2962.55×2017-12-31
2018-04-3055.91×2018-03-31
2018-05-3157.55×2018-03-31
2018-06-2959.15×2018-03-31
2018-07-3154.87×2018-06-30
2018-08-3155.78×2018-06-30
2018-09-2857.87×2018-06-30
2018-10-3153.82×2018-06-30
2018-11-3061.38×2018-09-30
2018-12-3157.38×2018-09-30
2019-01-3155.15×2018-09-30
2019-02-2814.52×2018-12-31
2019-03-2914.51×2018-12-31
2019-04-3013.7×2018-12-31
2019-05-3112.92×2019-03-31
2019-06-2814.29×2019-03-31
2019-07-3114.46×2019-03-31
2019-08-3016.17×2019-03-31
2019-09-3015×2019-03-31
2019-10-3115.91×2019-09-30
2019-11-2917.52×2019-09-30
2019-12-3117.99×2019-09-30
2020-01-3116.12×2019-09-30
2020-02-2815.21×2019-12-31
2020-03-3115.44×2019-12-31
2020-04-3018.22×2019-12-31
2020-05-2917.78×2020-03-31
2020-06-3018.25×2020-03-31
2020-07-3119.84×2020-06-30
2020-08-3120.55×2020-06-30
2020-09-3020.61×2020-06-30
2020-10-3017.38×2020-09-30
2020-11-3017.79×2020-09-30
2020-12-3118.42×2020-09-30
2021-01-2919.34×2020-09-30
2021-02-2618.08×2020-12-31
2021-03-3120×2020-12-31
2021-04-3019.65×2021-03-31
2021-05-2819.51×2021-03-31
2021-06-3019.99×2021-03-31
2021-07-3019.81×2021-03-31
2021-08-3122.61×2021-06-30
2021-09-3021.32×2021-06-30
2021-10-2920.75×2021-06-30
2021-11-3020.21×2021-09-30
2021-12-3122.86×2021-09-30
2022-01-3123.08×2021-09-30
2022-02-2823.02×2021-09-30
2022-03-3124.57×2021-09-30
2022-04-2923.7×2021-09-30
2022-05-3126.09×2021-09-30
2022-06-3024.72×2021-09-30
2022-07-2925.15×2021-09-30
2022-08-3124.42×2021-09-30
2022-09-3022.91×2021-09-30
2022-10-3127.47×2021-09-30
2022-11-3029.1×2021-09-30
2022-12-3026.69×2021-09-30
2023-01-3125.65×2021-09-30
2023-02-2823.54×2021-09-30
2023-03-3124.57×2021-09-30
2023-04-2824.36×2021-09-30
2023-05-3122.42×2021-09-30
2023-06-3022.56×2021-09-30
2023-07-3123.79×2021-09-30
2023-08-3126.05×2021-09-30
2023-09-2927.31×2021-09-30
2023-10-3125.98×2021-09-30
2023-11-3027.4×2021-09-30
2023-12-2929.27×2021-09-30
2024-01-3131.94×2021-09-30
2024-02-2921.93×2023-12-31
2024-03-2822.77×2023-12-31
2024-04-3021.94×2023-12-31
2024-05-3143.57×2024-03-31
2024-06-2844.51×2024-03-31
2024-07-3147.36×2024-03-31
2024-08-3057.7×2024-06-30
2024-09-3055.69×2024-06-30
2024-10-3155.34×2024-06-30
2024-11-2936.24×2024-09-30
2024-12-3133.4×2024-09-30
2025-01-3136.57×2024-09-30
2025-02-2840.75×2024-12-31
2025-03-3141.21×2024-12-31
2025-04-3038.48×2024-12-31
2025-05-3026.28×2025-03-31
2025-06-3025.46×2025-03-31
2025-07-3126.91×2025-03-31
2025-08-2923.52×2025-06-30
2025-09-3023.07×2025-06-30
2025-10-3124.39×2025-06-30
2025-11-2826.73×2025-09-30
2025-12-3125.33×2025-09-30
2026-01-3026.45×2025-09-30
2026-02-2727.28×2025-12-31
2026-03-3124.73×2025-12-31
2026-04-3024.34×2025-12-31
2026-05-2923.49×2026-03-31
2026-06-3025.26×2026-03-31
2026-07-3126.86×2026-03-31
2026-08-3126.75×2026-06-30
2026-09-2525.8×2026-06-30
Mean 24.69×Median 21.05×23% above median

ROIC

% · Annual / TTM

—
Amgen ROIC. Reported fiscal history.
Fiscal period% · Annual / TTM
FY 2009 Q2—
FY 2009 Q3—
FY 2009 Q4—
FY 2010 Q1—
FY 2010 Q2—
FY 2010 Q3—
FY 2010 Q414.99%
FY 2011 Q1—
FY 2011 Q213.9%
FY 2011 Q311.36%
FY 2011 Q411.33%
FY 2012 Q111.3%
FY 2012 Q211.82%
FY 2012 Q313.27%
FY 2012 Q412.76%
FY 2013 Q113.28%
FY 2013 Q213.38%
FY 2013 Q313.31%
FY 2013 Q412.21%
FY 2014 Q111.6%
FY 2014 Q212.2%
FY 2014 Q311.43%
FY 2014 Q411.08%
FY 2015 Q111.89%
FY 2015 Q211.53%
FY 2015 Q312.44%
FY 2015 Q413.61%
FY 2016 Q113.39%
FY 2016 Q213.65%
FY 2016 Q313.53%
FY 2016 Q414.14%
FY 2017 Q113.85%
FY 2017 Q213.9%
FY 2017 Q313.54%
FY 2017 Q43.49%
FY 2018 Q14.47%
FY 2018 Q24.75%
FY 2018 Q34.57%
FY 2018 Q418.75%
FY 2019 Q122.45%
FY 2019 Q222.79%
FY 2019 Q326.15%
FY 2019 Q422.74%
FY 2020 Q123.65%
FY 2020 Q222.57%
FY 2020 Q325.02%
FY 2020 Q423.43%
FY 2021 Q122.78%
FY 2021 Q218.7%
FY 2021 Q318.26%
FY 2021 Q419.72%
FY 2022 Q120.94%
FY 2022 Q224.11%
FY 2022 Q325.57%
FY 2022 Q425.47%
FY 2023 Q123.44%
FY 2023 Q224.3%
FY 2023 Q323.12%
FY 2023 Q414.23%
FY 2024 Q112.74%
FY 2024 Q211.78%
FY 2024 Q312.18%
FY 2024 Q411.31%
FY 2025 Q111.64%
FY 2025 Q212.72%
FY 2025 Q312.96%
FY 2025 Q414.43%
FY 2026 Q1—
FY 2026 Q2—

Capital allocation

% of tracked cash uses

$1,875M
Amgen capital allocation. Quarterly values. Missing values are unavailable.
PeriodCapexAcquisitionsBuybacksDividendsDebt repaymentsTracked uses
FY 2009 Q2100% · $139MUnavailable0% · $0MUnavailableUnavailable100% · $139M
FY 2009 Q3100% · $130MUnavailable0% · $0MUnavailableUnavailable100% · $130M
FY 2009 Q46.11% · $144M0% · $0M51.42% · $1,211MUnavailable42.46% · $1,000M100% · $2,355M
FY 2010 Q15.59% · $94M0% · $0M94.41% · $1,587MUnavailable0% · $0M100% · $1,681M
FY 2010 Q219.89% · $177M0% · $0M80.11% · $713MUnavailable0% · $0M100% · $890M
FY 2010 Q330.17% · $127M0% · $0M69.83% · $294MUnavailable0% · $0M100% · $421M
FY 2010 Q413.25% · $182M0% · $0M86.75% · $1,192M0% · $0M0% · $0M100% · $1,374M
FY 2011 Q13.31% · $100M13.36% · $403M0.46% · $14M0% · $0M82.86% · $2,500M100% · $3,017M
FY 2011 Q210.68% · $123M25.87% · $298M63.45% · $731M0% · $0M0% · $0M100% · $1,152M
FY 2011 Q34.53% · $120M0% · $0M85.83% · $2,272M9.63% · $255M0% · $0M100% · $2,647M
FY 2011 Q43.88% · $224M0% · $0M91.87% · $5,298M4.25% · $245M0% · $0M100% · $5,767M
FY 2012 Q15.04% · $144M33.92% · $969M48.13% · $1,375M9.98% · $285M2.94% · $84M100% · $2,857M
FY 2012 Q27.24% · $172M29.53% · $702M50.69% · $1,205M11.78% · $280M0.76% · $18M100% · $2,377M
FY 2012 Q310.94% · $173M20.18% · $319M51.23% · $810M17.65% · $279M0% · $0M100% · $1,581M
FY 2012 Q49.47% · $200M18.94% · $400M57.62% · $1,217M12.97% · $274M0.99% · $21M100% · $2,112M
FY 2013 Q14.11% · $158M0% · $0M21.65% · $832M9.19% · $353M65.05% · $2,500M100% · $3,843M
FY 2013 Q230.99% · $159M0% · $0M0% · $0M69.01% · $354M0% · $0M100% · $513M
FY 2013 Q333.08% · $175M0% · $0M0% · $0M66.92% · $354M0% · $0M100% · $529M
FY 2013 Q41.85% · $201M86.87% · $9,434M0% · $0M3.26% · $354M8.02% · $871M100% · $10,860M
FY 2014 Q119.98% · $172M12.08% · $104M0% · $0M53.43% · $460M14.52% · $125M100% · $861M
FY 2014 Q24.46% · $173M0.28% · $11M0% · $0M11.94% · $463M83.31% · $3,230M100% · $3,877M
FY 2014 Q322.4% · $170M0% · $0M0% · $0M61.13% · $464M16.47% · $125M100% · $759M
FY 2014 Q46.81% · $203M1.68% · $50M4.63% · $138M15.57% · $464M71.31% · $2,125M100% · $2,980M
FY 2015 Q19.04% · $118M0% · $0M35.53% · $464M45.87% · $599M9.57% · $125M100% · $1,306M
FY 2015 Q24.11% · $133M0% · $0M14.71% · $476M18.6% · $602M62.58% · $2,025M100% · $3,236M
FY 2015 Q38.59% · $138M0% · $0M46.33% · $744M37.3% · $599M7.78% · $125M100% · $1,606M
FY 2015 Q413.96% · $205M24.46% · $359M12.47% · $183M40.6% · $596M8.51% · $125M100% · $1,468M
FY 2016 Q19.13% · $156MUnavailable39.56% · $676M44% · $752M7.31% · $125M100% · $1,709M
FY 2016 Q27.98% · $188MUnavailable23% · $542M31.9% · $752M37.12% · $875M100% · $2,357M
FY 2016 Q34.91% · $167MUnavailable22.45% · $764M21.95% · $747M50.69% · $1,725M100% · $3,403M
FY 2016 Q47.68% · $227MUnavailable33.24% · $983M25.26% · $747M33.82% · $1,000M100% · $2,957M
FY 2017 Q17.62% · $168M0% · $0M26.56% · $586M38.4% · $847M27.43% · $605M100% · $2,206M
FY 2017 Q23.19% · $185M0% · $0M16.81% · $976M14.57% · $846M65.44% · $3,800M100% · $5,807M
FY 2017 Q38.75% · $158M0% · $0M44.82% · $809M46.43% · $838M0% · $0M100% · $1,805M
FY 2017 Q48.52% · $153M1.06% · $19M43.96% · $789M46.46% · $834M0% · $0M100% · $1,795M
FY 2018 Q11.31% · $155MUnavailable90.63% · $10,697M8.06% · $951M0% · $0M100% · $11,803M
FY 2018 Q23.9% · $187M0% · $0M67.64% · $3,244M18.04% · $865M10.43% · $500M100% · $4,796M
FY 2018 Q36.22% · $171M0% · $0M62.85% · $1,729M30.93% · $851M0% · $0M100% · $2,751M
FY 2018 Q45.9% · $225M0.05% · $2M55.72% · $2,124M22.04% · $840M16.29% · $621M100% · $3,812M
FY 2019 Q12.3% · $116M0% · $0M60.05% · $3,032M17.85% · $901M19.81% · $1,000M100% · $5,049M
FY 2019 Q22.36% · $144M0% · $0M39.66% · $2,415M14.45% · $880M43.52% · $2,650M100% · $6,089M
FY 2019 Q35.25% · $170M5.46% · $177M35.83% · $1,161M26.79% · $868M26.67% · $864M100% · $3,240M
FY 2019 Q41.21% · $188M86.25% · $13,440M7.02% · $1,094M5.52% · $860M0% · $0M100% · $15,582M
FY 2020 Q12.68% · $142MUnavailable18.14% · $961M17.84% · $945M61.34% · $3,250M100% · $5,298M
FY 2020 Q24.64% · $158MUnavailable16.3% · $555M27.67% · $942M51.4% · $1,750M100% · $3,405M
FY 2020 Q37.35% · $135M0% · $0M41.67% · $765M50.98% · $936M0% · $0M100% · $1,836M
FY 2020 Q44.6% · $173M0% · $0M32.05% · $1,205M24.79% · $932M38.56% · $1,450M100% · $3,760M
FY 2021 Q18.09% · $166MUnavailable42.43% · $871M49.49% · $1,016M0% · $0M100% · $2,053M
FY 2021 Q26.67% · $185MUnavailable56.99% · $1,581M36.34% · $1,008M0% · $0M100% · $2,774M
FY 2021 Q34.33% · $242M58.45% · $3,265M19.33% · $1,080M17.88% · $999M0% · $0M100% · $5,586M
FY 2021 Q43.7% · $287M11.47% · $890M18.6% · $1,443M12.76% · $990M53.48% · $4,150M100% · $7,760M
FY 2022 Q12.49% · $190MUnavailable83.36% · $6,360M14.15% · $1,080M0% · $0M100% · $7,630M
FY 2022 Q219.16% · $246MUnavailable0% · $0M80.84% · $1,038M0% · $0M100% · $1,284M
FY 2022 Q313.36% · $160M0% · $0M0% · $0M86.64% · $1,038M0% · $0M100% · $1,198M
FY 2022 Q46.51% · $340M73.56% · $3,839M0% · $0M19.93% · $1,040M0% · $0M100% · $5,219M
FY 2023 Q115.74% · $344MUnavailable0% · $0M52.04% · $1,137M32.22% · $704M100% · $2,185M
FY 2023 Q219.22% · $271MUnavailable0% · $0M80.78% · $1,139M0% · $0M100% · $1,410M
FY 2023 Q311.6% · $248MUnavailable0% · $0M53.32% · $1,140M35.08% · $750M100% · $2,138M
FY 2023 Q417.93% · $249MUnavailable0% · $0M82.07% · $1,140M0% · $0M100% · $1,389M
FY 2024 Q115.99% · $230MUnavailableUnavailable84.01% · $1,208M0% · $0M100% · $1,438M
FY 2024 Q28.36% · $238MUnavailableUnavailable42.47% · $1,209M49.17% · $1,400M100% · $2,847M
FY 2024 Q37.01% · $257MUnavailableUnavailable33% · $1,210M59.99% · $2,200M100% · $3,667M
FY 2024 Q423.54% · $371MUnavailableUnavailable76.46% · $1,205M0% · $0M100% · $1,576M
FY 2025 Q19.81% · $411MUnavailableUnavailable30.53% · $1,279M59.67% · $2,500M100% · $4,190M
FY 2025 Q213.93% · $369MUnavailableUnavailable48.32% · $1,280M37.75% · $1,000M100% · $2,649M
FY 2025 Q313.55% · $436MUnavailableUnavailable39.84% · $1,282M46.61% · $1,500M100% · $3,218M
FY 2025 Q433.35% · $642MUnavailableUnavailable66.65% · $1,283M0% · $0M100% · $1,925M
FY 2026 Q124.53% · $712MUnavailableUnavailable46.78% · $1,358M28.69% · $833M100% · $2,903M
FY 2026 Q227.36% · $513MUnavailableUnavailable72.64% · $1,362M0% · $0M100% · $1,875M

Tracked cash uses · SBC excluded

Sources and calculations

Company filings · USD · Last checked 2026-10-18. Missing inputs remain unavailable. Your chart selection and layout are saved in this browser for Amgen.

All charts share the selected dates. Quarterly/Yearly changes fiscal charts; valuation keeps completed daily closes on a published TTM basis. Later restatements can delay that basis. Historical mean, median and pricing labels use the selected range and do not estimate intrinsic fair value.

SBC deduction is an optional economic-cost scenario for FCF-based metrics. Missing SBC never becomes zero.

Revenue
Reported revenue from company filings.
Free cash flow
Operating cash flow − reported cash capital investment. PPE purchases are preferred; the productive-assets fallback also includes software and intangibles. Reflects the SBC option and can differ from issuer-defined FCF.
Net margin
Reported net income / revenue × 100.
P/E
Completed closing price × diluted shares / TTM earnings attributable to common shareholders.
ROIC
NOPAT / average invested capital × 100. NOPAT = operating income × (1 − effective tax rate). Invested capital = equity including noncontrolling interests + debt − cash and equivalents. Average uses period end and one year earlier.
Capital allocation
Reported cash uses as a percentage of tracked uses. Missing categories remain unavailable; SBC is noncash and excluded.
Reported revenue and sources